Wird geladen...
The immune response‐related mutational signatures and driver genes in non‐small‐cell lung cancer
Immune checkpoint blockade (ICB) therapy has achieved remarkable clinical benefit in non‐small‐cell lung cancer (NSCLC), but our understanding of biomarkers that predict the response to ICB remain obscure. Here we integrated somatic mutational profile and clinicopathologic information from 113 NSCLC...
Gespeichert in:
| Veröffentlicht in: | Cancer Sci |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
John Wiley and Sons Inc.
2019
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6676111/ https://ncbi.nlm.nih.gov/pubmed/31222843 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14113 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|